Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended Aug. 31, 2018. All are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.bioasis.us/investors/.
Bioasis also announces that Christopher Lowe, M.B.A., of FLG Partners, who has served as the Company’s chief financial officer (CFO) since Oct. 2, 2017, has resigned. We thank Chris and FLG Partners for their diligence and effective oversight of the Company. The Company is in the process of identifying a replacement CFO and Mark Day, Ph.D., director, president and chief executive officer, will serve as interim CFO. With Mr. Lowe’s departure, the Company has retained a public accounting and advisory services firm, which will be better able to locally support Bioasis in Connecticut, to provide accounting and bookkeeping services. Manning Elliot continues to be the Company’s auditor.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Mark Day, Ph.D., Director and President & Chief Executive Officer
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030006024/en/